Prescribing Information

Important Safety Information

YUVEZZI™

Thank you for participating in this approximately 5-minute survey. To the best of your ability, please answer the following questions regarding your experience and that of your patients using YUVEZZI, indicated for the treatment of presbyopia in adults.1 Please note that your responses are confidential and will not be shared with outside parties.

An answer to each question is required unless otherwise noted.

1. Approximately how many patients have you prescribed YUVEZZI to so far?
2. What types of patients have you prescribed YUVEZZI to? 

(Select all that apply)
3. Based on your experience so far, which aspects of YUVEZZI do you consider key strengths?
(Select all that apply)
4. Based on your experience and on feedback received from your patients, how would you describe the duration of effect of YUVEZZI for meeting your patients’ near-vision needs?
5. Based on your experience and on feedback received from your patients, how would you rate the tolerability profile of YUVEZZI so far?
6. Overall, how would you rate your experience with YUVEZZI compared to other topical miotic drops you have prescribed?
7. Based on your experience so far, how do you expect your prescribing of YUVEZZI to change over the next several months?
8. Looking ahead, how do you anticipate positioning YUVEZZI for appropriate presbyopia patients?
9. How likely are you to recommend YUVEZZI to a colleague?
Please share your practice ZIP code
(5 digits)
*denotes required field if opting in
First Name
Last Name
Email Address
Specialty Type
National Provider Identifier (NPI)

I understand I am giving Tenpoint Therapeutics™, its affiliates, and business partners permission to use the personal information provided in this registration form, as described in this authorization. I understand that the information I am providing may be used by Tenpoint Therapeutics™ and its contracted third-party representatives to provide me with health and product information and related services concerning health conditions and treatments. By submitting this form, I consent to these uses and am confirming that I have read and agree to the Tenpoint Therapeutics™ Terms of Use and Privacy Policy. I understand that Tenpoint Therapeutics™ and its contracted third-party representatives will NOT sell or rent my personal information, and that the information provided in this form will be used in accordance with the Tenpoint Therapeutics™ Privacy Policy. I agree that this authorization will expire ten (10) years from the date submitted, or until my participation in the program ends through my cancellation. I acknowledge that I am submitting this form voluntarily, and that I am at least 18 years of age.

Tap for safety information

 

Indication

YUVEZZI is indicated for the treatment of presbyopia in adults.

Important Safety Information

Contraindications

YUVEZZI is contraindicated in patients with known hypersensitivity to the active ingredients or to any of the excipients.

Warnings and Precautions

Advise patients to not drive or operate machinery if vision is not clear (e.g., blurred vision). In addition, patients may experience temporary dim or dark vision with miotics. Advise patients to exercise caution in night driving and other hazardous activities in poor illumination.

Rare cases of retinal tear and detachment have been reported with miotics. Individuals with pre-existing retinal disease are at increased risk. Examination of the retina is advised in all patients prior to the initiation of therapy. Advise patients to seek immediate medical care with sudden onset of flashes of lights, floaters, or vision loss.

YUVEZZI is not recommended to be used when iritis is present.

Avoid touching the vial to the eye, eyelids, or to any other surface.

YUVEZZI may potentiate syndromes associated with vascular insufficiency.

Drug Interactions

  • Antihypertensives/cardiac glycosides, tricyclic antidepressants, and monoamine oxidase inhibitors: caution advised.
  • CNS depressants: consider the possibility of additive or potentiating effects.

Adverse Reactions

The most common adverse reactions were eye pain upon instillation, visual impairment, eye irritation upon instillation, and headache. The majority of adverse events were mild, transient, and self-resolving.

To report SUSPECTED ADVERSE REACTIONS, contact Visus Therapeutics, Inc., at 1-888-735-0821 or FDA at 1-800-FDA-1088 or
www.fda.gov/medwatch.

For additional safety information, see the full Prescribing Information.

Reference: 1. YUVEZZI Prescribing Information. Visus Therapeutics, Inc.; 2026.

Thank you for your time! If you have any additional questions or comments, please connect with your Tenpoint Sales Representative or contact us directly.

Tenpoint branded circle

You are now leaving tenpointtherapeutics.com.
Are you sure you want to continue?

No